Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Aldeyra plans FDA appeal for reproxalap dry eye treatment application

Aldeyra Therapeutics (NASDAQ:ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA) seeking review of the agency’s decision not to approve reproxalap, its investigational therapy for dry eye disease.

Leia mais: Aldeyra plans FDA appeal for reproxalap dry eye treatment application